Navigation Links
Chest Physicians Now Suggest Early Intervention for Certain Blood Clots in DVT
Date:7/29/2008

2008 American College of Chest Physicians (ACCP) Guidelines Will Increase

Use of Trellis(R) Peripheral Infusion System

NORTHBROOK, Ill., July 29 /PRNewswire/ -- The American College of Chest Physicians (ACCP) has published new evidence-based clinical guidelines for physicians that for the first time suggest the use of pharmacomechanical thrombolysis for acute iliofemoral deep vein thrombosis (DVT) in conjunction with anticoagulation drug therapy. The new guidelines appear in the July supplement to the CHEST journal.

"This is a major change in the recommendations for the care of these patients with extensive DVT, and represents a major advance in treatment. Adopting an initial strategy of thrombus removal will improve the quality of life of these patients and potentially avoid recurrent DVT in the future," stated Anthony J. Comerota, MD, FACS, FACC, Director of the Jobst Vascular Center and Adjunct Professor of Surgery, University of Michigan.

"The recommendation to treat certain cases of acute DVT with pharmacomechanical thrombolysis adds an important tool to help treat the acute problem as well as to minimize the long-term disability of post-thrombotic syndrome (PTS) in patients," added Katharine L. Krol, MD, Director, Vascular Interventional Radiology, CorVasc MDs, Indianapolis, IN and recent past president of the Society of Interventional Radiology (SIR).

The new Venous Thromboembolic (VTE) Disease guidelines represent an evolution from the previous ACCP standard which recommended the use of anticoagulation drug therapy alone for the treatment of DVT. For complete information on the new ACCP VTE Guidelines, visit http://www.TheNewGuidelines.org.

While anticoagulation alone mitigates the risk of clot propagation and pulmonary embolism, it often fails to clear the blockage. This residual thrombus can lead to venous hypertension, valvular insufficiency, skin ulcerations and post-thrombotic syndrome.

"The publication of the new 2008 ACCP guidelines suggesting the use of pharmacomechanical thrombolysis clearly establishes a new standard for thrombolytic therapy. We believe the Trellis(R) Isolated Pharmacomechanical Thrombolysis method provides the best available combination of safety and efficacy," remarked Scott Cramer, President and CEO of Bacchus Vascular, Inc.

Isolated pharmacomechanical thrombolysis using the Trellis Peripheral Infusion System from Bacchus Vascular, Inc. to deliver thrombolytic directly into a desired treatment segment has proven to be a rapid, effective and safe method of treating patients with acute DVT. The Trellis device is the only DVT treatment system that isolates the thrombus and targets the thrombolytic treatment.

About Bacchus Vascular

Bacchus Vascular, Inc. is a privately held medical device company dedicated to the treatment of peripheral vascular disease. Dr. Thomas Fogarty, a noted inventor and cardiovascular surgeon, founded the company with the vision of transforming blood clot removal from peripheral blood vessels into a fast, simple, minimally-invasive catheter-based procedure. Thousands of patients suffering from DVT and other occlusive vascular diseases have been treated worldwide to date using the company's Trellis(R) Peripheral Infusion System and other products.

For more information, visit http://www.bacchusvascular.com.

For complete information on the new ACCP VTE Guidelines, visit: http://www.TheNewGuidelines.org.


'/>"/>
SOURCE Bacchus Vascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Rochester Medical Announces Third Quarter 2008 Earnings Conference Call July 31, 2008
2. Medline Signs 3-Year Purchasing Agreement for Mouth Rinse From Chester Labs
3. Rochester Medical Announces Second Quarter 2008 Earnings Conference Call April 29, 2008
4. Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility
5. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
6. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
7. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
8. National ePrescribing Patient Safety Initiative Supports Senates Call for Physicians to Adopt Electronic Prescribing, Improving Patient Safety
9. Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product
10. Lilly Backs Federal Legislation to Inform the Public on Payments to Physicians
11. More Than 700 Physicians and Administrators Participate in the Visian ICL Growth Program(TM) Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
Breaking Biology Technology:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
Breaking Biology News(10 mins):